Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing (NCT07384767) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing
United States220 participantsStarted 2026-06-01
Plain-language summary
The purpose of this research study is to evaluate the efficacy and safety of topical timolol 0.5% for secondary intention wound healing following 1) Mohs micrographic surgery, 2) standard surgical excision, OR 3) electrodesiccation and curettage (ED\&C). Please note that healing by secondary intention refers to when a wound heals naturally without surgical closure.
To evaluate the efficacy of topical timolol 0.5%, 220 participants will be recruited. Participants will be placed into one of two groups: The treatment group or the control group.
1. The treatment group will receive a topical timolol 0.5% solution, which will be applied to their wound daily for 12 weeks.
2. The control group will receive standard care with the addition of hydrogel, which will also be applied to their wound daily for 12 weeks.
During this 12-week period, both groups will be required to upload photos of their wound healing to their MyChart account at weeks 3, 6, 9, and 12. These photos will be reviewed by the investigator to assess wound healing. Re-epithelialization and earlier complete wound healing will be compared between both groups to determine the efficacy of topical timolol 0.5% solution compared to the standard of care.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Male or female subject of any race 18 years old or older
. Patient opt to heal by secondary intention healing after discussion of reconstructive options following excision
. Patients undergoing Mohs micrographic surgery, standard surgical excision, or electrodesiccation and curettage (ED\&C) whose wounds are managed by secondary intention healing.
. Willing to send photos of ulcer at 3 week intervals with ruler measuring length by width
. Able to give informed consent themselves
Exclusion criteria
. Cyst excisions (due to concern for inflammation)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Site shows evidence of infection (defined as a moderate or severe rating of all of the following clinical signs/symptoms: 1) increased warmth, 2) increased pain, 3) erythema, and 4) malodorous exudate at Screening or at Randomization (Visit 1), OR total organism count \> 1 x 105 colony forming units (CFU) from the screening visit study ulcer culture sample)
. Severe COPD/asthma/cardiac arrhythmia
. Hx of documented beta blocker allergy
. Cognitive impairment
. Has medically documented history of Human Immunodeficiency Virus (HIV)
. Has active malignancy on the study limb
. Has immunodeficiency as defined by serum IgG, IgA, and IgM less than one-half the lower limit of normal